MED28 is highly expressed in breast, colon, and prostate cancers, and MED28 induces cancer cell proliferation via the mitogen-activated protein kinase kinase-1 (MAP2K1) signaling pathway [10,11,12]. This evidence concerns the gene MAP2K1 and prostate carcinoma.